Tyra Biosciences
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, ...
Latest News
6 days ago · prnewswire.com
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent HighlightsReported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients Completed $400 million financing, providing additional capital to advance dabogratinib's 3x3 strategy Cash runway through 2030 with cash, cash equivalents and marketable securities of $700.5 million as of September 30, 2026 CARLSBAD, Calif., Nov. 10, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate progress.
11 days ago · prnewswire.com
Tyra Biosciences to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference 2026 Format: One-on-one investor meetingsDate/Time: November 10, 2026Location: Boston, MA Jefferies Global Healthcare Conference in London Format: Hybrid presentation and one-on-one investor meetingsPresentation Date/Time: Monday, November 16, 2026 at 11:30 AM GMT A live webcast of the Jefferies presentation can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
1 month ago · zacks.com
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 WeeksTyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2 months ago · prnewswire.com
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsCARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22.029 per share, which equals the offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.
2 months ago · seekingalpha.com
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC TranscriptTyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
2 months ago · benzinga.com
Why Is Tyra Biosciences Stock Sinking Wednesday?Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and identifying a 60 mg once-daily dose to support planned registrational studies.
2 months ago · investors.com
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer ResultsTyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.
2 months ago · barrons.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to ImpressTyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.
3 months ago · prnewswire.com
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 - CARLSBAD, Calif., Aug. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress.
6 months ago · prnewswire.com
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TYRA